Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry

How do patients with inflammatory bowel disease want their biological therapy administered?

(2010) Patrick B Allen et al.   BMC GASTROENTEROLOGY

A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease

(2010) David S. Kotlyar et al.   Clinical Gastroenterology and Hepatology

Concomitant Use of Immunomodulators with Anti-TNF in Crohns Disease: Yes or No?

(2010) Johannes Meier et al.   CURRENT DRUG TARGETS

Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review

(2010) Abderrahim Oussalah et al.   CURRENT DRUG TARGETS

Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology

(2010) Thomas W. Lee et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Rheumatoid Arthritis Disease-modifying Antirheumatic Drug Intervention and Utilization Study: Safety and Etanercept Utilization Analyses from the RADIUS 1 and RADIUS 2 Registries

(2010) A. GIBOFSKY et al.   JOURNAL OF RHEUMATOLOGY

What is the optimal therapy for Crohn’s disease: step-up or top-down?

(2010) Ming Valerie Lin et al.   Expert Review of Gastroenterology & Hepatology

Adalimumab safety in global clinical trials of patients with Crohnʼs disease

(2009) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease

(2009) Frank Hoentjen et al.   WORLD JOURNAL OF GASTROENTEROLOGY

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up

(2008) C. W. LEES et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS